Results 111 to 120 of about 4,829 (180)

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]

open access: yesAm J Cardiovasc Drugs
Spadafora L   +16 more
europepmc   +1 more source

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

open access: yesOpen Forum Infect Dis
Aparicio-Minguijón E   +8 more
europepmc   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

open access: yesBlood Res
Hur JY   +10 more
europepmc   +1 more source

<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]

open access: yesEJHaem
Haméon C   +9 more
europepmc   +1 more source

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

open access: yesHaematologica, 2017
Anna Vidal-Crespo   +13 more
doaj   +1 more source

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. [PDF]

open access: yesBlood Adv
Heyman BM   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy